

Abstract Submission

Abstract submission guidelines

Abstracts

The Meeting Secretariat and Scientific Committee welcome you and invite you to submit an abstract in order to be included in the scientific program.

This year most of the program will be comprised of oral presentations selected from abstracts submitted by August 18th 2024.

Details of the terms and submission processes are listed below.

Abstract submission

The final date for abstract submission is August 18th 2024.

Abstracts may be submitted only via email: e.tareshet@gmail.com

Please read the rules of submission before submitting your abstract.

Guidelines for abstract submission

Before you begin, please prepare the following information:

Presenting author's contact details

- Title, full first and last name(s)
- Affiliation details: department, institution / hospital, city, state (if relevant), country
- Mail address
- Phone number

Author and co-authors' details

- Title, full first and last name (s)
- Affiliation details: department, institution / hospital, city, state (if relevant), country
- Email address

Please specify your preferred presentation type: Oral or Poster

Abstract Title - limited to 25 words in UPPER CASE

Abstract Layout – abstracts should use the following structured format:

- Introduction/ Background
- Methods/ Materials
- Results
- Conclusions
- References (Optional)

Rules for Abstract Submission:

- All abstracts must be submitted and presented in clear English and spelling quality that is suitable for publication.
- The Scientific Committee will review all the abstracts, and once complete, you will get information about the type of presentation you will present.
- Upon submission, the Abstract Submitter confirms that the abstract has been revised and that all information is correct. The content of this abstract cannot be modified or corrected after final submission and the author is aware that it will be published exactly as submitted.
- The abstract submission constitutes acceptance of the authors regarding its publication (e.g. meeting website, programs, other promotions, etc.).
- The Abstract Submitter warrants and represents that he/she is the exclusive owner or has the rights of all the information and content (Hereafter: “Content”) provided to The 28 Annual Meeting – The Israeli Society for Research, Prevention & Treatment of Atherosclerosis. The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
- Submitted abstracts containing research by clinical trials on human or animal subjects must be approved by the Helsinki Committee or by the local Institutional Review Board.
- The organizers have the right to remove any abstract which does not comply with the above.
- Upon submission the Abstract Submitter confirms that the contact details saved in the system are those of the corresponding author, who will be notified about the status of the abstract, and will be responsible for informing the other authors about the status of the abstract